Advertisement

The progestin ST 1435—rapid metabolism in man

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Parenterally administered ST 1435 (Nestorone) is highly potent for contraception, and ovulation can be inhibited with very low serum levels of ST 1435. Orally administered ST 1435 is ineffective in various laboratory animals, presumably due to extensive first-pass metabolism. Thus, ST 1435 has been proposed for lactational contraception, to be metabolized by the suckling infant. We have studied the metabolism of ST 1435 in female volunteers following oral (10 mg), intravenous (iv) (0.1 mg) and transdermal (4.5–9.0 mg) routes of ST 1435 administration. Preliminary studies using rats were performed to develop the methodology of high performance-liquid chromatography (HPLC) fractionation and ST 1435-RIA detection. Rat portal serum revealed 4 distinct peaks of immunoreactive material with the retention times (Rt's) of 7.5, 10, 14.5 and 17.5 min (ST 1435 = 10 min). In systemic serum, only the peak with the Rt of 7.5 min could be detected. Therefore, orally administered ST 1435 is very effectively metabolized by the rat liver; this also explains the previously observed lack of biological effects of oral ST 1435. Following oral administration of ST 1435 to two women, the Rt of the major peak was 10 min. The magnitude of the ST 1435 peak decreased rapidly, and at 24h following ingestion, no ST 1435 could be detected by this method. The tMath Eq of ST 1435 was ~ 1–2h. In addition, two minor peaks with Rt's of 4.5 and 16 min could be detected with the ST 1435 RIA at 1–4h following oral ingestion. Competitive receptor binding assays using the human uterine progesterone receptors (hPR) revealed that the ST 1435 fraction exhibits strong binding affinity towards the hPR; thus, in the human, a small fraction of biologically active ST 1435 seems to escape from the first-pass metabolism following oral intake. Following iv and transdermal administration of ST 1435, the only detectable peak with ST 1435-RIA was that of ST 1435. Similar magnitude of the ST 1435 peaks following oral administration of 10 mg and iv administration of 0.1 mg indicated that the bioavailability of ST 1435 is low. These data seem to confirm the suspicion that orally administered ST 1435 is also rapidly metabolized in the human, therefore encouraging further evaluation of ST 1435 during lactation. However, the rapid metabolism seen after oral intake can be successfully circumvented by sustained parenteral administration of ST 1435.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kurunmäki H
        • Toivonen J
        • Lähteenmäki PLA
        • Luukkainen T
        Intracervical release of ST-1435 for contraception.
        Contraception. 1984; 29: 411-421
        • Laurikka-Routti M
        • Haukkamaa M
        • Heikinheimo O
        A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.
        Contraception. 1990; 41: 111-120
        • Coutinho E
        • DaSilva AR
        • Carreira C
        • Sivin I
        Long-term contraception with a single implant of the progestin ST-1435.
        Fertil Steril. 1981; 36: 737-740
        • Laurikka-Routti M
        • Haukkamaa M
        A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side-effects.
        Fertil Steril. 1992; 58: 1142-1147
        • Haukkamaa M
        • Laurikka-Routti M
        • Heikinheimo O
        Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in saliva.
        Contraception. 1991; 44: 269-276
        • Suhonen S
        • Haukkamaa M
        • Lähteenmäki P
        • Holmström T
        Endometrial effect of transdermal estradiol and progestin ST-1435 in postmenopausal women.
        Fertil Steril. 1992; 57: 1211-1215
        • Lähteenmäki PLA
        • Weiner E
        • Lähteenmäki P
        • Johansson E
        • Luukkainen T
        Pituitary and ovarian function during contraception with one subcutaneous implant releasing the progestin ST-1435.
        Contraception. 1982; 25: 299-306
        • Haukkamaa M
        • Laurikka-Routti M
        • Heikinheimo O
        • Moo-Young A
        Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
        Contraception. 1992; 45: 49-55
        • Lähteenmäki PLA
        Contraceptive action of a synthetic progestin^.
        in: ST-1435 (Thesis). University of Helsinki, Helsinki, Finland1986
        • Lähteenmäki PLA
        • Hammond G
        • Luukkainen T
        Serum non-protein bound percentage and distribution of the progestin ST-1435: no effect of ST-1435 treatment on plasma SHBG and CBG binding capacities.
        Acta Endocrinologica. 1983; 102: 307-313
        • Odlind V
        • Lithell H
        • Kurunmäki H
        • et al.
        ST-1435: development of an implant.
        in: Zatuchini G Goldsmith A Shelton J Sciarra J Long-acting contraceptive delivery systems. Harper and Row, Philadelphia1984: 441-449
        • Lähteenmäki P
        • Weiner E
        • Lähteenmäki PLA
        • Johansson E
        • Luukkainen T
        Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435.
        Contraception. 1981; 23: 63-75
        • Haukkamaa M
        Binding of progesterone by rat myometrium and by human myometrium in late pregnancy.
        J Steroid Biochem. 1974; 5: 73-79
        • Korenman SG
        Relationship between estrogen inhibitory activity and binding to cytosol of rabbit and human uterus.
        Endocrinology. 1970; 87: 1119-1123
        • Coutinho E
        • DaSilva AR
        • Kraft H
        Fertility control with subdermal Silastic capsules containing a new progestin (ST-1435).
        Int J Fertil. 1976; 21: 103-108
        • Odlind V
        • Lithell H
        • Selinus I
        • Vessby B
        Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
        Upsala J Med Sci. 1984; 89: 151-158
        • Laurikka-Routti M
        Serum lipids, blood pressure, body weight and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST 1435.
        Obstet Gynecol. 1992; 80: 855-859
        • Lähteenmäki PLA
        • Diaz S
        • Miranda P
        • Croxatto H
        • Lähteenmäki P
        Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.
        Contraception. 1990; 42: 555-562
        • Lähteenmäki PLA
        Intestinal absorption of ST-1435 in rats.
        Contraception. 1984; 30: 143-151
        • Noé G
        • Salvatierra A
        • Heikinheimo O
        • Maturana X
        • Croxatto H
        Pharmaco-kinetics and bioavailability of ST 1435 administered by different routes.
        Contraception. 1993; 48: 548-556
        • Laurikka-Routti M
        • Haukkamaa M
        • Lähteenmäki P
        Suppression of the ovarian function with the transdermally given synthetic progestin ST 1435.
        Fertil Steril. 1992; 58: 680-684